141 related articles for article (PubMed ID: 15177268)
1. Co-stimulation and plaque-antigen-specific T-cell responses in atherosclerosis.
Buono C; Lichtman AH
Trends Cardiovasc Med; 2004 May; 14(4):166-72. PubMed ID: 15177268
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal Echinococcus multilocularis infection in C57BL/6 mice affects CD40 and B7 costimulator expression on peritoneal macrophages and impairs peritoneal T cell activation.
Mejri N; Gottstein B
Parasite Immunol; 2006 Aug; 28(8):373-85. PubMed ID: 16879309
[TBL] [Abstract][Full Text] [Related]
3. Co-stimulatory molecules in and beyond co-stimulation - tipping the balance in atherosclerosis?
Gerdes N; Zirlik A
Thromb Haemost; 2011 Nov; 106(5):804-13. PubMed ID: 21979444
[TBL] [Abstract][Full Text] [Related]
4. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro.
Cywinski AL; Dunnion DJ; Teobald I; Tucker VC; Browning MJ
Tissue Antigens; 2006 Aug; 68(2):115-26. PubMed ID: 16866881
[TBL] [Abstract][Full Text] [Related]
5. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
Croft M
Nat Rev Immunol; 2003 Aug; 3(8):609-20. PubMed ID: 12974476
[TBL] [Abstract][Full Text] [Related]
6. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
7. Co-stimulatory molecules as potential targets for therapeutic intervention in allergic airway disease.
Kallinich T; Beier KC; Gelfand EW; Kroczek RA; Hamelmann E
Clin Exp Allergy; 2005 Dec; 35(12):1521-34. PubMed ID: 16393317
[TBL] [Abstract][Full Text] [Related]
8. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
[TBL] [Abstract][Full Text] [Related]
9. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
10. Time courses of B7 family molecules expressed on activated T-cells and their biological significance.
Sun ZW; Qiu YH; Shi YJ; Tao R; Chen J; Ge Y; Hu YM; Ma HB; Shi Q; Zhang XG
Cell Immunol; 2005; 236(1-2):146-53. PubMed ID: 16165113
[TBL] [Abstract][Full Text] [Related]
11. CD27 and CD70 in T cell and B cell activation.
Borst J; Hendriks J; Xiao Y
Curr Opin Immunol; 2005 Jun; 17(3):275-81. PubMed ID: 15886117
[TBL] [Abstract][Full Text] [Related]
12. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
13. Emerging paradigms of T-cell co-stimulation.
Kroczek RA; Mages HW; Hutloff A
Curr Opin Immunol; 2004 Jun; 16(3):321-7. PubMed ID: 15134781
[TBL] [Abstract][Full Text] [Related]
14. T cells in atherogenesis: for better or for worse?
Robertson AK; Hansson GK
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2421-32. PubMed ID: 16973967
[TBL] [Abstract][Full Text] [Related]
15. New understanding of immunological mechanisms.
Saalmüller A
Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
[TBL] [Abstract][Full Text] [Related]
16. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
17. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis.
Lee J; Zhuang Y; Wei X; Shang F; Wang J; Zhang Y; Liu X; Yang Y; Liu L; Zheng Q
J Mol Cell Cardiol; 2009 Feb; 46(2):169-76. PubMed ID: 19056397
[TBL] [Abstract][Full Text] [Related]
18. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
19. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
[TBL] [Abstract][Full Text] [Related]
20. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H
Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
